This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Zofenopril is an ACE inhibitor indicated in the treatment of hypertension.
- Generic Name
- Zofenopril
- DrugBank Accession Number
- DB13166
- Background
Zofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Zofenopril (DB13166)
- Weight
- Average: 429.55
Monoisotopic: 429.106850573 - Chemical Formula
- C22H23NO4S2
- Synonyms
- Zofenil
- Zofénopril
- Zofenopril
- Zofenoprilum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acute myocardial infarction (ami) •••••••••••• Treatment of High blood pressure (hypertension) •••••••••••• Used in combination to treat Mild to moderate hypertension Combination Product in combination with: Hydrochlorothiazide (DB00999) •••••••••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AAngiotensin-converting enzyme inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide Abaloparatide may increase the hypotensive activities of Zofenopril. Acebutolol Acebutolol may increase the hypotensive activities of Zofenopril. Aceclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Zofenopril. Acemetacin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Zofenopril. Acetylsalicylic acid The therapeutic efficacy of Zofenopril can be decreased when used in combination with Acetylsalicylic acid. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Zofenopril calcium 88ZQ329PU2 81938-43-4 NSYUKKYYVFVMST-LETVYOFWSA-L - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image BIFRIL PLUS Zofenopril (30 MG) + Hydrochlorothiazide (12.5 MG) Tablet, film coated Oral บริษัท เอ. เมนารินี (ประเทศไทย) จำกัด 2017-05-09 Not applicable Thailand 
BIFRIL PLUS 30/12.5 MG FILM TABLET, 28 ADET Zofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg) Tablet, film coated Oral ULAGAYLAR İLAÇ SAN. VE TİC. A.Ş. 2007-11-26 2022-06-30 Turkey 
BIFRIL PLUS 30/12.5 MG FILM TABLET, 84 ADET Zofenopril calcium (30 mg) + Hydrochlorothiazide (12.5 mg) Tablet, film coated Oral ULAGAYLAR İLAÇ SAN. VE TİC. A.Ş. 2007-11-26 2022-06-30 Turkey BIFRIZIDE Zofenopril calcium (30 MG) + Hydrochlorothiazide (12.5 MG) Tablet, coated Oral Istituto Luso Farmaco D'italia S.P.A. 2014-07-08 Not applicable Italy 
BIFRIZIDE Zofenopril calcium (30 MG) + Hydrochlorothiazide (12.5 MG) Tablet, coated Oral Istituto Luso Farmaco D'italia S.P.A. 2014-07-08 Not applicable Italy
Categories
- ATC Codes
- C09BA15 — Zofenopril and diuretics
- C09BA — ACE inhibitors and diuretics
- C09B — ACE INHIBITORS, COMBINATIONS
- C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C — CARDIOVASCULAR SYSTEM
- Drug Categories
- ACE Inhibitors and Diuretics
- Agents Acting on the Renin-Angiotensin System
- Agents causing angioedema
- Agents causing hyperkalemia
- Amino Acids
- Amino Acids, Cyclic
- Amino Acids, Peptides, and Proteins
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Cardiovascular Agents
- Enzyme Inhibitors
- Imino Acids
- Protease Inhibitors
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Proline and derivatives
- Alternative Parents
- N-acyl-L-alpha-amino acids / Thiobenzoic acids and derivatives / Benzoic acids and derivatives / Thiophenol ethers / Pyrrolidine carboxylic acids / Benzoyl derivatives / N-acylpyrrolidines / Alkylarylthioethers / Tertiary carboxylic acid amides / Thioesters show 10 more
- Substituents
- Alkylarylthioether / Aromatic heteromonocyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzoic acid or derivatives / Benzoyl / Carbonyl group / Carbothioic s-ester / Carboxamide group show 27 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- thioester, aryl sulfide, N-acyl-L-amino acid, L-proline derivative (CHEBI:78539)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 290ZY759PI
- CAS number
- 81872-10-8
- InChI Key
- IAIDUHCBNLFXEF-MNEFBYGVSA-N
- InChI
- InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1
- IUPAC Name
- (2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylic acid
- SMILES
- C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N1C[C@H](C[C@H]1C(O)=O)SC1=CC=CC=C1
References
- General References
- Nilsson P: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:25-30. [Article]
- Mallion JM: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:13-8. [Article]
- AIFA Product Information: Bifril (zofenopril calcium) film-coated tablets [Link]
- External Links
- KEGG Drug
- D08688
- PubChem Compound
- 92400
- PubChem Substance
- 347829273
- ChemSpider
- 83422
- BindingDB
- 50084629
- 39990
- ChEBI
- 78539
- ChEMBL
- CHEMBL331378
- ZINC
- ZINC000003775162
- Wikipedia
- Zofenopril
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Hypertension 3 4 Recruiting Treatment Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 15.000 mg Tablet, coated Oral 15 mg Tablet Oral 30 mg Tablet, coated Oral 30 mg Tablet, film coated Oral 7.5 mg Tablet, film coated Oral Tablet, film coated Oral 30 mg Tablet Oral Tablet, coated Oral Tablet, film coated Oral Tablet, film coated Oral 15 MG Tablet, film coated Oral 60 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00311 mg/mL ALOGPS logP 3.64 ALOGPS logP 4.31 Chemaxon logS -5.1 ALOGPS pKa (Strongest Acidic) 3.5 Chemaxon pKa (Strongest Basic) -1.3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 74.68 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 116.82 m3·mol-1 Chemaxon Polarizability 46.1 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-053r-0465900000-2a77f2eb6d7d6a8021b1 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-2623900000-b7d81fdd80cf9665b0f5 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0930100000-210777289f6c9dd1e452 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-9510100000-9cc00c2d8b594dd15f47 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0bt9-2911000000-c149ce26e96b5fb4ac72 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-2900000000-5a0f4fd2ac8202f18c65 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 203.1022559 predictedDarkChem Lite v0.1.0 [M-H]- 190.83356 predictedDeepCCS 1.0 (2019) [M+H]+ 204.7551559 predictedDarkChem Lite v0.1.0 [M+H]+ 193.69228 predictedDeepCCS 1.0 (2019) [M+Na]+ 202.8713559 predictedDarkChem Lite v0.1.0 [M+Na]+ 201.00893 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
- Gene Name
- ACE
- Uniprot ID
- P12821
- Uniprot Name
- Angiotensin-converting enzyme
- Molecular Weight
- 149713.675 Da
References
- Ambrosioni E: Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7(1):17-24. [Article]
Drug created at February 11, 2017 15:59 / Updated at June 05, 2021 09:12